louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07019792: Postoperative Pain and Bacterial Reduction in Oval Canals After Instrumentation With Different Noval Rotary Files Systems
Official title: Effect of Different Rotary Files Systems on Post-operative Pain and Bacterial Reduction in Lower Single Canal Posterior Teeth With Necrotic Pulp: Prospective Double Blinded Clinical Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Bacterial Count Reduction in Oval Canal After Rotary Instrumentation With Different Systems
Post-operative Pain After Rotary Instrumentation of Oval Canal With Different Systems
Keywords: post operative pain
Protaper Ultimate
Hyflex EDM
XP rsie
TruNatomy
Bacterial
Oval canal
Lead sponsor: King Abdullah University Hospital
Sponsor class: OTHER
Collaborators: name: Jordan University of Science and Technology
First posted: 2025-06-13
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Postoperative pain after endodontic treatment can affect a patient's quality of life. It is reported that debris extrusion after the instrumentation technique can influence postoperative pain. As a result, the aim of this clinical trial is to compare the recent rotary systems (TruNatomy, ProTaper Ultimate, Hyflex EDM and XP- rise rotary files systems) in terms of apical extrusion defined by post-operative pain and their role in reducing the bacterial count inside the canal

Detailed description: One hundred and twenty lower premolar teeth will be included in the study(n=120). Teeth will be randomly assigned to one of the 4 groups(n=30). Preoprative pain will be recorded before root canal treatment. Postoperative pain will be recorded using visual analogue scale (VAS) at 6 hours,12 hours, 1day, 2 days, 3 days, 4 dayse and five days after the root canal treatment. Bacterial count before and after instrumentation will be determined using culturing methods to determine the bacterial count reduction.

Eligibility criteria: Inclusion Criteria:

* Medically fit
* Age ranges from 18-65 year
* Restorable teeth
* Necrotic teeth and symptoms free
* Lower premolars teeth (single canal posterior teeth)
* Necrotic pulps

Exclusion Criteria:

* Medically compromised
* Non-restorable teeth
* Open apex canal
* The past 12-hour history of analgesic intake before treatment.
* Patients with a history of antibiotics intake in the last 3 months before treatment.
* Pregnant females.
* Symptomatic patient.
* Pulpal diagnosis is not necrotic pulp.
* Retreatment cases

Primary outcomes:
measure: Postoperative pain
timeFrame: at 6hours,12 hours, 24 hours, 2 days, 3 days, 4 days and five days after the root canal treatment
measure: Bacterial count reduction
timeFrame: Sample will be collected before and directly after canal prepeartion
Secondary outcomes:
Other outcomes:
Locations:
city: Irbid
country: Jordan
facility: Ruba Mustafa
Study officials:
References:
Clinical trial NCT00181792: Family Risk Analysis of Substance Use in Attention Deficit Hyperactivity Disorder (ADHD) Youth Treated With Concerta
Official title: Family Risk Analysis of Substance Use in ADHD Youth Treated With Concerta
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: ADHD
Smoking
Keywords: ADHD
smoking
familial risk
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2005-09-16
Enrollment: 70
Sex: ALL
Minimum age (years): 6
Maximum age (years): 55
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: FAMILY_BASED
Sampling method: NON_PROBABILITY_SAMPLE
Study population: First-degree relative between the ages of 6-55 years of a family member (proband) between the ages of 12-17 with the DSM-IV diagnosis of ADHD

Brief summary: The researchers will study 100 families over three years, each with a child (proband) between the ages of 12-17, with the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of ADHD. The researchers hypothesize smoking will be familial and ADHD probands with a family history of tobacco use will be at increased risk for early initiation and persistence of smoking, compared to ADHD probands with no family history of tobacco use.

Detailed description: As Attention Deficit Hyperactivity Disorder (ADHD) is a documented risk factor for smoking in adolescents, and as theoretical considerations suggest that ADHD and tobacco use may share common underlying mechanisms, the proposed study looks to examine the association between smoking and ADHD. Since both ADHD and smoking are known to be familial disorders, one approach to examine the nature of the association between the two disorders is to conduct a familial risk analysis comparing ADHD youth who smoke and ADHD youth who don't smoke. Another approach is to conduct a genetic study, to identify candidate genes associated with nicotine abuse and dependence in ADHD youth and relatives.

This study includes:

1. assessment of psychopathology and substance use/dependence,
2. assessment of the family environment, and
3. assessment of molecular genetics in 100 families with at least one child (proband) between the ages of 12-17 with a DSM-IV diagnosis of ADHD.

Eligibility criteria: Inclusion Criteria:

* First-degree relative between the ages of 6-55 years of a family member (proband) between the ages of 12-17 with the DSM-IV diagnosis of ADHD

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Cambridge
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Paul Hammerness, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05069792: Utrecht COhort for Lung Cancer Outcome Reporting and Trial Inclusion (U-COLOR)
Official title: Utrecht COhort for Lung Cancer Outcome Reporting and Trial Inclusion (U-COLOR)
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Lung Cancer
Lead sponsor: UMC Utrecht
Sponsor class: OTHER
First posted: 2021-10-06
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who are referred to the Department of Pulmonology or the Department of Radiotherapy of the UMC Utrecht for treatment of lung cancer will be eligible to be enrolled in the U-COLOR cohort.

Brief summary: Objective: 1) To collect information on patient characteristics, short- and long-term clinical and patient-reported outcomes; and 2) to create an infrastructure for efficient, fast, and pragmatic randomized evaluation of new interventions.

Study design: Observational, prospective cohort study, according to the 'TwiCs' design.

Study population: All patients with lung cancer referred to the Department of Pulmonology or the Department of Radiotherapy of the UMC Utrecht.

Main study parameters/endpoints: Clinical parameters (performance status, co-morbidity, oncological history, symptoms, imaging, technical and treatment data), clinical endpoints (toxicity, reintervention and survival), and patient-reported outcomes.

Detailed description: The prospective U-COLOR cohort (Utrecht COhort for Lung cancer Outcome Reporting and trial inclusion), aims to:

* Gather data on natural disease progression, treatment response, disease recurrence, complications, quality of life and survival of patients with lung cancer;
* Collect a patient group willing to participate in studies;
* Facilitate multiple, parallel randomized controlled trials within the cohort.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years;
* Radiographic and/or histologic proof of lung cancer;
* Referred to Department of Pulmonology or the Department of Radiotherapy for treatment.

Exclusion Criteria:

* Mental disorder or cognitive dysfunction that hinders the patient's ability to understand the informed consent procedure and/or study details;
* Patients with severe psychiatric disorders;
* Inability to understand the Dutch language.

Primary outcomes:
measure: Change in Health-related Quality of Life
timeFrame: Up to 10 years after treatment
measure: Occurence of toxicity (adverse events)
timeFrame: Up to 10 years after treatment
measure: Readmission
timeFrame: Up to 10 years after treatment
measure: Survival
timeFrame: Up to 10 years after treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: University Medical Center Utrecht
Study officials:
affiliation: UMC Utrecht
name: Helena M Verkooijen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01382992: A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: Carcinoma, Non-Small-Cell Lung
erbB-1
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
Collaborators: name: Peking University People's Hospital
First posted: 2011-06-27
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Non-small cell lung cancer patients who were diagnosed or treated in Peking Union Medical College Hospital or Peking University People's Hospital

Brief summary: EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.


Eligibility criteria: Inclusion Criteria:

* Non-small cell lung cancer
* Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy)
* Informed Consent

Exclusion Criteria:

* N/A

Primary outcomes:
measure: To determine the consistence of EGFR mutation status in paired tissue and plasma samples
timeFrame: 3 months
Secondary outcomes:
measure: To determine the EGFR mutation status in Chinese NSCLC
timeFrame: 3month
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
affiliation: Peking Union Medical College Hospital
name: Mengzhao Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03148392: Assess Differences in Pain Following Cryo and Radiofrequency Atrial Fibrillation Ablation
Official title: A Prospective Comparison of Quality of Life Following Atrial Fibrillation Ablation Using the Arctic Front Advance Cryo Balloon Compared to Contact Force Sensing Radiofrequency Catheter Ablation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Atrial Fibrillation
Lead sponsor: Langhorne Cardiology Consultants, Inc.
Sponsor class: OTHER
Collaborators: name: Medtronic
First posted: 2017-05-11
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Cardiology

Brief summary: The primary objective is to assess any differences in patient quality of life between Cryo Balloon ablation and Radiofrequency ablation in the treatment of atrial fibrillation. The study will also assess any differences in the amount and duration of pain medication required after the ablation.

Detailed description: Currently there are several different accepted techniques for performing ablation of atrial fibrillation. The two primary techniques currently in use in our center for atrial fibrillation are Cryo Balloon and Radiofrequency ablation.

Based on personal observation, it is felt that patients undergoing Radiofrequency ablation have a higher incidence of chest discomfort and subsequently a greater requirement for pain medications post procedure as compared to those patients undergoing Cryo ablation.

Eligibility criteria: Inclusion Criteria:

* Paroxysmal atrial fibrillation who are advised either Cryoablation or Radiofrequency ablation for treatment.

Exclusion Criteria:

* Persistent atrial fibrillation
* Pregnant
* Taking pain medications for acute or chronic conditions at the time of the procedure.
* Undergo a combination of Cryoablation and Radiofrequency ablation
* Radiofrequency group who undergo ablation beyond pulmonary vein isolation

Primary outcomes:
measure: Pain Intensity Measurement
timeFrame: 7 Days
Secondary outcomes:
measure: Health Status and Activity Measurement
timeFrame: 7 Days
measure: Pain Medication Assessment
timeFrame: 30 Days
Other outcomes:
Locations:
city: Pensacola
country: United States
facility: Cardiology Consultants
state: Florida
Study officials:
affiliation: Cardiology Consultants
name: Sumit Verma, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05494892: Development of a Research Agenda for Rehabilitation Research
Official title: Entwicklung Einer Forschungsagenda Für Die Reha-Forschung in Der Österreichischen Pensionsversicherungsanstalt (PVA) [Development of a Research Agenda for Rehabilitation Research in the Austrian Pension Insurance Institution (PVA)]
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Research Agenda
Conditions Influencing Health Status
Keywords: Research Agenda
Applied Rehabilitation Research
Expert Survey
Expert Interviews
Delphi Survey
Lead sponsor: Pensionsversicherungsanstalt
Sponsor class: OTHER
First posted: 2022-08-10
Enrollment: 163
Sex: ALL
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: International and Austrian experts from science and research related to rehabilitation, cooperation partners, representatives of the rehabilitation facilities of the PVA, as well as decision-makers of the PVA were included.

Brief summary: An internal research department was established in the course of an organisational reform of the Pension Insurance Institution in 2020 for the evidence-based development of its own services in Austria. The focus is on the transfer of findings into practice and the scientific community. As part of an initial assessment of the current situation, an organisation-specific research agenda is being systematically developed.

The project design is based on a multi-perspective and multi-method approach. After obtaining experts' opinions (interview) from different settings and areas, a consensus on necessary fields of action will be worked out after synthesising the results via a Delphi survey.


Eligibility criteria: Inclusion Criteria:

* Researchers who conduct scientific research in the field of rehabilitation in Austria, Germany and Switzerland
* People working in rehabilitation facilities (in therapy or administration) in Austria, Germany and Switzerland

Exclusion Criteria:

* Failure to obtain the declaration of consent

Primary outcomes:
measure: Identification of priorities in applied rehabilitation research
timeFrame: April 2021 - November 2021
measure: Weighting of the identified priorities in research
timeFrame: May 2023 - August 2023
Secondary outcomes:
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Pensionsversicherungsanstalt
Study officials:
affiliation: Pensionsversicherungsanstalt
name: Doreen Stöhr, Mag.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05778292: Effect of Different VV ECMO Flows on Lung Perfusion Monitored by EIT
Official title: Effect of Different VV ECMO Flows on Lung Perfusion Monitored by EIT: an Observational Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critical Illness
Keywords: VV ECMO
EIT
Lung perfusion
Lead sponsor: Wuhan Union Hospital, China
Sponsor class: OTHER
First posted: 2023-03-21
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with respiratory failure supported on VV ECMO

Brief summary: The purpose of this study is to investigate the feasibility of using electric impedance tomography (EIT) to monitor lung perfusion during veno-venous (VV) extracopreal membrane oxygenation (ECMO) support, as well as the effect of different ECMO flows on lung perfusion monitored by EIT.

Detailed description: This is a monocentric obsevensional study that uses EIT to monitor lung perfusion during VV ECMO support and the effect of different ECMO flows on lung perfusion as measured by EIT. Patients on VV ECMO who meet the withdrawal criteria as determined by clinical experts will have their ECMO flow gradually reduced. EIT lung ventilation and perfusion monitoring were performed at various ECMO flows.

Eligibility criteria: Inclusion Criteria:

1. Patients aged ≥ 18 and ≤ 70 years；
2. Patients supported with VV ECMO for respiratory failure；
3. Patients are intubated and mechanically ventilated.

Exclusion Criteria:

1. EIT contraindications such as chest wound dressing, pacemaker installation, defibrillator, etc;
2. Patients who did not sign the informed consent form;
3. Pulmonary embolism;
4. Pneumothorax;
5. Medium to plenty of chest water;
6. Atrial fibrillation or other malignant arrhythmia leads to a decrease in cardiac output;
7. Refractory shock;
8. Severe chronic heart and lung disease has existed in the past;
9. BMI\>35 kg/m2;
10. Intra-abdominal pressure \>20mmHg.

Primary outcomes:
measure: Lung perfusion at different VV ECMO flows
timeFrame: up to 24hour
Secondary outcomes:
measure: Lung ventilation at different VV ECMO flows
timeFrame: up to 24hour
measure: Lung deadspace region at different VV ECMO flows
timeFrame: up to 24hour
measure: Lung shunt region at different VV ECMO flows
timeFrame: up to 24hour
measure: Lung ventilation/perfusion matching at different VV ECMO flows
timeFrame: up to 24hour
measure: Recirculation at different VV ECMO flows
timeFrame: up to 24hour
Other outcomes:
Locations:
city: Wuhan
country: China
facility: Xiaobo Yang
state: Hubei
Study officials:
References:
Clinical trial NCT02526992: Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.
Official title: Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Rheumatoid Arthritis
Lead sponsor: Centre Hospitalier Universitaire de Saint Etienne
Sponsor class: OTHER
First posted: 2015-08-18
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease in adults and is characterized by chronic inflammation of the joints leading to their destruction, resulting in a major loss of function.

The investigators propose a pilot study for studying changes in bone microarchitecture with High Resolution peripheral micro Computerized Tomography (HR-pQCT) in patients with RA treated with anti-TNF(Tumor Necrosis Factor), with the measurement of micro-architectural parameters in subchondral area near an inflammatory joint during the first 12 months of initiation of an anti-TNF therapy (Infliximab®, Etanercept®, Adalimumab®).


Eligibility criteria: Inclusion Criteria:

* Men from 18 to 65 years old
* Women from 18 years old to menopause
* Patient with a polyarthritis rheumatoid no controlled by the usual treatment (DAS28\>3)
* Patient affiliated or beneficiary of a national insurance system
* Patient with signed consent

Exclusion Criteria:

* Concomitant osseous disease (Paget's disease, osteomalacia...)
* Endocrinopathy defined on biological criteria (Cushing's disease, hyperthyroidism, hypogonadism...)
* Patients under protection of justice
* Refusal consent

Primary outcomes:
measure: trabecular volume (bone volume / tissue volume) in percent for bone microarchitecture measured by HR-pQCT
timeFrame: 12 months after intitiation of anti-TNF treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Saint-etienne
country: France
facility: CHU de SAINT-ETIENNE
Study officials:
affiliation: CHU de SAINT-ETIENNE
name: Thierry THOMAS, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03860792: Therapeutic Diets in Alzheimer's Disease
Official title: Therapeutic Diets in Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Alzheimer Disease
Lead sponsor: University of Kansas Medical Center
Sponsor class: OTHER
Collaborators: name: National Institute on Aging (NIA)
First posted: 2019-03-04
Enrollment: 80
Sex: ALL
Minimum age (years): 50
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: By doing this study, researchers hope to learn how the ketogenic and Therapeutic Lifestyles Changes diets affect cognition in patients with Alzheimer's disease.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of AD by current McKhann et al. criteria
* CDR global score of 0.5 or 1
* Agreed cooperation from an appropriate study partner
* Speaks English as primary language
* Age 50 to 90
* No medication changes within the past 30 days

Exclusion Criteria:

* Resides in a nursing home or dementia special care unit, or cannot control diet
* A potentially confounding serious medical risk including insulin-requiring diabetes, cancer requiring chemotherapy or radiation within the past 5 years, or a recent cardiac event (i.e. heart attack, angioplasty, etc.)
* Participating in another clinical trial or using an investigational drug or therapy within 30 days of the Screening Visit
* A history of renal stones

Primary outcomes:
measure: Change in cognitive performance on the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADASCog11)
timeFrame: Baseline, 12 Weeks
measure: Change in cognitive performance on the Mini-Mental State Exam (MMSE)
timeFrame: Baseline, 12 Weeks
measure: Change in cognitive performance on the Logical Memory Test (LMT)
timeFrame: Baseline, 12 Weeks
measure: Change in cognitive performance by Stroop test
timeFrame: Baseline, 12 Weeks
measure: Change in Clinical Dementia Rating (CDR)
timeFrame: Baseline, 12 Weeks
Secondary outcomes:
measure: Change in cerebral concentration of N-Acetylaspartate (NAA)
timeFrame: Baseline, 12 Weeks
measure: Change in blood platelet mitochondrial function
timeFrame: Baseline, 6 Weeks, 12 Weeks
measure: Change in self-reported symptoms by study partner
timeFrame: Baseline, 6 Weeks, 12 Weeks
Other outcomes:
measure: Change in blood ketone levels induced by ketogenic diet
timeFrame: Baseline, 6 Weeks, 12 Weeks
measure: Proportion of days positive for urinary ketone production
timeFrame: Daily for 90 days (the length of the diet intervention)
measure: Dietary intake characterization prior to and after ketogenic diet initiation
timeFrame: Baseline, 6 Weeks, 12 Weeks
Locations:
city: Fairway
country: United States
facility: Clinical and Translational Science Unit
state: Kansas
Study officials:
References: